ABBV (NYSE) - AbbVie Inc

Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US00287Y1091
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for ABBV (NYSE) - AbbVie Inc
Market Cap. 251,447m USD
Enterprise Value 314,718m USD (+25%)
GiC Sector Health Care
GiC Group Pharmaceuticals, Biotechnology & Life Sciences
GiC Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-01-02


Fundamental 2.21
Dividend 8.51
Technical 5.87
Performance -10.00
Analysts 3.69
Price / Fair Price TR 1.06
Price / Fair Price DCF todo


Growth TTM -5.10%
CAGR 5y 11.81%
CAGR / Mean Drawdown 5y 1.15
Sharpe Ratio TTM -0.44
Alpha vs SP500 TTM -8.91
Beta vs SP500 5y weekly 0.71
Volatility GJR Garch 1y 24.78%
CAPM 8.47%
Correlation TTM 0.38
Max Drawdown 5y 35%
Mean Drawdown 5y 10.3%
Price / SMA 200 days 7.97%
Current Volume 7333.4k
Average Volume 5728.1k


Rate TTM 5.78
Yield TTM 4.20%
Div. CAGR 5y 9.46%
Consistency of Dividends all time 100.0%